<DOC>
	<DOC>NCT00568945</DOC>
	<brief_summary>This trial has the primary goal to show that BAY68-4986 can lower the ventricular rate in patients with the indication persistent atrial fibrillation.</brief_summary>
	<brief_title>Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Male and/or female (without childbearing potential) white patients History of persistent or permanent atrial fibrillation 18 to 75 years of age Patients with highrisk cardiovascular diseases Stroke or myocardial infarction Relevant pathological changes in the ECG or echocardiography Medication affecting ventricular response in Afib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Capadenoson</keyword>
</DOC>